Evidence map›Paper›PMID 35805885›Full record

ArticleInternational journal of molecular sciences2022

Exploration of Somatostatin Binding Mechanism to Somatostatin Receptor Subtype 4.

Rita Börzsei, Balázs Zoltán Zsidó, Mónika Bálint, Zsuzsanna Helyes, Erika Pintér, Csaba Hetényi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rita BörzseiDepartment of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
Balázs Zoltán ZsidóDepartment of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
Mónika BálintDepartment of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
Zsuzsanna HelyesDepartment of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.
Erika PintérDepartment of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.ORCID 0000-0001-9898-632X
Csaba HetényiDepartment of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, 7624 Pécs, Hungary.ORCID 0000-0002-8013-971X
University of Pecs · HU

Funding

European Union, co-financed by the European Social Fund EFOP-3.6.1-16-2016-00004Hungarian Academy of Sciences János Bolyai Research ScholarshipHungarian National Research, Development and Innovation Office K123836Hungarian National Research, Development and Innovation Office K134214National Research, Development and Innovation Fund of Hungary, financed under the EGA-13 funding scheme and Lorand Eotvos research Network Project no. TKP2021-EGA-13National Research, Development and Innovation Fund of Hungary, financed under the EGA 16 funding scheme Project no. TKP2021-EGA-16New National Excellence Program of the Ministry for Innovation and Technology ÚNKP-21-3-IINew National Excellence Program of the Ministry for Innovation and Technology ÚNKP-21-5PTE ÁOK PTE ÁOK-KA 2021/KA-2021-39
6 · The paper itself

Abstract

Somatostatin (also named as growth hormone-inhibiting hormone or somatotropin release-inhibiting factor) is a regulatory peptide important for the proper functioning of the endocrine system, local inflammatory reactions, mood and motor coordination, and behavioral responses to stress. Somatostatin exerts its effects via binding to G-protein-coupled somatostatin receptors of which the fourth subtype (SSTR4) is a particularly important receptor mediating analgesic, anti-inflammatory, and anti-depressant effects without endocrine actions. Thus, SSTR4 agonists are promising drug candidates. Although the knowledge of the atomic resolution-binding modes of SST would be essential for drug development, experimental elucidation of the structures of SSTR4 and its complexes is still awaiting. In the present study, structures of the somatostatin-SSTR4 complex were produced using an unbiased, blind docking approach. Beyond the static structures, the binding mechanism of SST was also elucidated in the explicit water molecular dynamics (MD) calculations, and key binding modes (external, intermediate, and internal) were distinguished. The most important residues on both receptor and SST sides were identified. An energetic comparison of SST binding to SSTR4 and 2 offered a residue-level explanation of receptor subtype selectivity. The calculated structures show good agreement with available experimental results and indicate that somatostatin binding is realized via prerequisite binding modes and an induced fit mechanism. The identified binding modes and the corresponding key residues provide useful information for future drug design targeting SSTR4.

Indexed as

Receptors, SomatostatinSomatostatinAnalgesicsPhagocytosisSignal TransductionAnalgesicsReceptors, SomatostatinSomatostatindynamicsinteractionpeptidepocketselectivitysite

Identifiers

PMID35805885
PMCPMC9266823
OpenAlexW4283270358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.